Spermidine Composition to Mitigate Nicotinamide Metabolic Side Effects

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for cardiovascular diseases, particularly those targeting lipid-modifying compounds like nicotinamide, often cause adverse effects on glucose and insulin homeostasis, such as glucose intolerance and obesity, with limited therapeutic options and significant side effects.

Innovation Solution

A composition comprising spermidine and/or its pharmaceutically acceptable salts, administered alone or in combination with nicotinamide, nicotinic acid, and/or their salts, to mitigate the adverse effects on glucose and insulin homeostasis caused by nicotinamide, improving cardiovascular health while reducing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nicotinamide is administered to treat cardiovascular diseases, then lipid modification and cardiovascular protection are improved, but adverse effects on glucose and insulin homeostasis occur

Engineering Contradiction:
Improvecardiovascular protectionVSAvoidadverse effects on glucose and insulin homeostasis
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Spermidine acts as a mediator substance that counteracts the harmful metabolic effects of nicotinamide. The patent combines nicotinamide (for cardiovascular protection) with spermidine (to protect glucose and insulin homeostasis), where spermidine mediates the protection against adverse effects without interfering with the primary therapeutic action of nicotinamide on the cardiovascular system.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a composite pharmaceutical composition containing both nicotinamide and spermidine. This composite approach allows the simultaneous delivery of two active substances with complementary functions: nicotinamide provides cardiovascular benefits while spermidine mitigates metabolic side effects, achieving a more balanced therapeutic profile.

Inventive Principle:
Principle #40Composite materials

2Reliability

If statins are used for lipid modification, then cardiovascular risk is reduced, but new-onset diabetes and myopathy occur

Engineering Contradiction:
Improvecardiovascular risk reductionVSAvoidnew-onset diabetes and myopathy
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Spermidine serves as a protective intermediary that counteracts the metabolic disturbances caused by statin therapy. By administering spermidine alongside or after statins, it mediates protection against statin-induced diabetes and myopathy while allowing the cardiovascular benefits of statins to persist.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention converts the harmful metabolic effects of statin therapy into a manageable condition by using spermidine to stimulate autophagy and improve cellular metabolism. The adverse effects (metabolic disturbances) are transformed into an opportunity to enhance cellular health through spermidine-induced autophagic processes.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If acetylsalicylic acid is administered for cardiovascular prevention, then thrombotic events are reduced, but hemorrhagic events increase

Engineering Contradiction:
Improvethrombotic event preventionVSAvoidhemorrhagic events
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the physiological parameters of platelet function and vascular health by introducing spermidine. Spermidine modifies the balance between pro-thrombotic and pro-hemorrhagic factors through its effects on endothelial function and platelet activation, allowing aspirin to work more selectively against thrombosis while reducing hemorrhagic risk.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP4203935B1Spermidine for use in the prevention and/or alleviation of adverse effects caused by nicotinamide
Publication Date: 2025.07.23 TLL THE LONGEVITY LABS GMBH
  • EP4203935B1 patent drawingFigure 1~2a
  • EP4203935B1 patent drawingFigure 2b~2c
  • EP4203935B1 patent drawingFigure 3a~3b

AI summary

The present invention relates to compositions comprising spermidine and/or a pharmaceutically acceptable salt thereof for use in the prevention and/or alleviation of side effects caused by nicotinamide, nicotinic acid and/or a pharmaceutically acceptable salt thereof.